Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
May 6, 2026 | Durbin PLC, Expanded access, Global sourcing, Medicine supply, NHS, Uniphar
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing and supply capabilities and strengthening its ability to respond to both local and international healthcare demands.
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
New rebrand unites UK operations under Uniphar’s global sourcing network, expanding reach and resilience in healthcare supply
Durbin PLC, a leading global provider of pharmaceutical products and services, today announced it has officially rebranded as Uniphar, fully aligning with Uniphar | Global Sourcing.
Against the backdrop of widespread medicine shortages[1], Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing and supply capabilities and strengthening its ability to respond to both local and international healthcare demands.
Established services delivered under the Durbin PLC name, including Aid & Development, International Sales, Pharmaceutical Services and Women’s Health will now be supported by Uniphar’s global network, combining local expertise with international scale to support the UK healthcare sector, including the NHS, while meeting global demand.
“In a market increasingly challenged by medicine shortages and intensifying supply chain pressures, trading as Uniphar and joining Uniphar | Global Sourcing gives us the scale, agility and reach to source critical products quickly and reliably, ensuring the right medicines reach patients at the right time,” said Simon Hayes, UK Managing Director of Uniphar | Global Sourcing.
Durbin PLC’s transition to Uniphar and integration into Uniphar | Global Sourcing alongside several established brands including BModesto, BMclinical, BMmedical, Doncaster Pharma, SynCo Pharma, Uniphar Clinical, Durbin UK, Durbin PTSI US, Pharmasource, Ostomysource and Orspec Pharma.
“By integrating ten global companies into Uniphar | Global Sourcing, we’re well positioned to support organisations like the NHS and meet demand for essential medicines,” said Dermot Ryan, Chief Operating Officer of Uniphar Group. “This transition demonstrates our commitment to building an integrated global sourcing business, strengthening our identity and enhancing the value we deliver to the UK healthcare sector and worldwide.”
Central to this capability is Uniphar’s new strategically located, purpose-built pharmaceutical distribution hub at Dove Valley Park in Derbyshire, designed to support clinical-to-commercial supply chains across the UK. Situated within the Midlands’ Golden Logistics Triangle, the site offers direct access to the A50 and East Midlands Airport, enabling rapid nationwide reach within four hours of 90% of the UK population.
Spanning approximately 113,000 sq. ft, the facility provides scalable capacity supported by enhanced cold-chain infrastructure, ambient and chilled storage, controlled drugs vaults and GDP-aligned operations. This infrastructure underpins Uniphar’s ability to deliver secure, efficient and compliant distribution, ensuring product integrity and continuity of supply for customers and patients.
For more information visit https://uniphar.com/globalsourcing/
[1]House of Commons Library (2025) Medicines shortages. UK Parliament Research Briefing, 4 September 2025. Available at: https://commonslibrary.parliament.uk/research-briefings/cbp-9997/
This content was provided by Uniphar
Company Details
Latest Content from Uniphar
J‑Pharma Co., Ltd. and Uniphar Announce Advancement of Nanvuranlat into Phase 3 Clinical Development Following FDA Alignment and Initial Patient Enrollment
Strategic partnership enables direct progression to Phase 3, bypassing additional Phase 2 study, as first patients are randomized in global trial TOKYO, Japan and DUBLIN, Ireland — [June 16, 2026] J‑Pharma Co., Ltd., a clinical-stage biotechnology…
Durbin PLC becomes Uniphar, bolstering medicine access amidst growing healthcare demands
Against the backdrop of widespread medicine shortages, Durbin PLC’s rebrand to Uniphar and integration into Uniphar | Global Sourcing represents a strategic move to address industry-wide challenges, expanding its sourcing…
Strategies to enhance the provider and patient EAP experience
Expanded access programs (EAPs) play a multifaceted role in the drug development life cycle, serving as a critical bridge between clinical trials and commercial availability.
Uniphar | Clinical merges with BMclinical to strengthen global clinical trial services
Leading global healthcare services provider Uniphar announces a strategic merger between Uniphar | Clinical and BMclinical, reinforcing Uniphar | Clinical’s integrated clinical supply offering and solidifying its position as a trusted partner to pharmaceutical and biotech companies worldwide. As part of Uniphar’s global platform supporting…
Uniphar announces U.S. expansion, integrating leading companies and appointing new senior leadership
– New integration aligns U.S. operations, unifying RRD BioPharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs under the Uniphar brand. – Mike Ebhardt is appointed President of Uniphar Pharma…
Uniphar On Track to Achieve SBTi Target of Halving Scope 1 and 2 Emissions by 2030
[Dublin, 9th October 2025] Uniphar, a global leader in pharmaceutical and medtech solutions, is making progress towards its near-term Science Based Targets initiative (SBTi) goal of halving Scope 1 and…
Streamlining European expansion for cell and gene therapies
Tom Smith, Strategic Director, Cell and Gene Therapies, Uniphar, discusses the essential elements biotechs need for commercial success in Europe’s unique market when developing cell and gene therapies (CGTs). Europe…
Current CGT landscape and future outlook
What makes CGT unique Cell and gene therapy (CGT) is a unique treatment that uses cells and genetic material to treat and cure diseases. Personalized to the patient, CGT’s offer…
Building for Success: Aligning Preclinical and Phase 1 Strategy with Commercial Goals
This article concludes our three-part series on preparing cell and gene therapies (CGTs) for successful launch and long-term viability. The first article explored the unique scientific and logistical challenges of…
Navigating the complexities of launch preparation for Cell and Gene Therapy
Cell and gene therapies (CGT) provide transformative treatment that can treat conditions that were previously considered untreatable. As described in the previous article in this series, most CGTs target patients…
- 1
- 2